Background
==========

Publications have reported hypermethylation of the promoter region of cancer-suppressor genes is common in peripheral blood in early stage NSCLC or several years before clinical diagnosis. This indicated that detection of methylation status in body fluids such as serum or sputum can be an effective method for NSCLC screening or for early diagnosis. These cancer-suppressor genes include P16 \[[@b1-medscimonit-25-5518]\], P53, RARβ \[[@b2-medscimonit-25-5518]\], MGMT \[[@b3-medscimonit-25-5518]--[@b5-medscimonit-25-5518]\], and *RASSF1A*. *RASSF1A*, also known as ras association domain-containing protein 1 gene, is associated with the pathogenesis of a variety of cancers when there is loss or altered expression of this gene, and hypermethylation of the promoter region is known to cause *RASSF1A* gene loss of expression. RASSF1A is one of the most frequently epigenetically inactivated tumor-suppressor genes in carcinomas. As a component of the Ras/PI3K/AKT, Ras/RAF/MEK/ERK, and Hippo cancer pathways, inactivation of RASSF1A is an important factor contributing to pathogenesis and progression of malignant carcinomas. Hypermethylation of *RASSF1A* gene in serum or sputum has been widely reported \[[@b6-medscimonit-25-5518]--[@b8-medscimonit-25-5518]\]. However, its diagnostic performance as a biomarker is unclear because of the small sample sizes of previous related publications. Therefore, we performed a meta-analysis by pooling all relevant published studies to assess its performance in clinical diagnosis.

Material and Methods
====================

Databases electronic searching
------------------------------

Authors Zhang Zhen and Dong Lixin independently searched PubMed, EMBASE, OVID, Cochrane Library, CNKI, and CBM databases to find published studies on *RASSF1A* gene promoter hypermethylation and NSCLC. The MESH search terms were: non-small cell lung cancer; NSCLC; hypermethylation; *RASSF1A*; and Ras association domain-containing protein 1. The relevant publications identified from the above databases were initially screened by EndNote and excluded duplicate publications and data. The papers were independently reviewed by 2 reviewers for tile, abstract, and full text to find suitable publications. The publications searching and inclusion procedures are shown in [Figure 1](#f1-medscimonit-25-5518){ref-type="fig"}.

Publication inclusion and data extraction
-----------------------------------------

Publications initially identified through searching the databases were further evaluated and underwent data extraction. The study inclusion criteria were: (1) case-control or cohort studies related to *RASSF1A* gene promoter hypermethylation and NSCLC; (2) All patients included in each individual study were diagnosed as having NSCLC by cytology or pathology confirmation; (3) Methylation of the *RASSF1A* gene promoter region was assessed by MSP; and (4) Studies published in English or Chinese. The publication exclusion criteria were: (1) Studies published in languages other than English or Chinese; (2) Small cell lung cancer; and (3) *RASSF1A* gene promoter hypermethylation detection in cancer tissue not serum or sputum.

Data extraction
---------------

Two reviewers independently reviewed the included studies and general information, including names of first and corresponding authors, year published, methylation detection methods, and specimens used for detection. Data on true-positive, false-positive, false-negative, and true-negative for DNA methylation as a biomarker in diagnosis of NSCLC were extracted from all included articles and were crossed-checked by 2 reviewers.

Statistical analysis
--------------------

Before pooling the effect sizes of sensitivity, specificity, positive likelihood ratio (+LR), negative likelihood ratio (-LR), and diagnostic odds ratio (DOR), the heterogeneity across the 12 publications was first evaluated with the I^2^ test. Fixed- (without statistical heterogeneity) or random-effects models (with statistical heterogeneity) were used for pooling the data. Sensitivity was calculated as tp/(tp+fp) and specificity as tn/(tn+fp). P\<0.05 was regarded as indicating a statistically significant difference.

Results
=======

Characteristics of the 12 included publications
-----------------------------------------------

Initially, 93 studies relevant to *RASSF1A* promoter hypermethylation as a biomarker in diagnosis of NSCLC were identified. After further screening, 81 publications were excluded because they were duplicate publications, case reports, or reviews, or if they did not contain sufficient data to calculation the diagnostic performance. Finally, 12 studies with 826 NSCLC cases and 598 controls were included ([Figure 1](#f1-medscimonit-25-5518){ref-type="fig"}). All of the 12 included studies used MSP assay as the hypermethylation detection method. Five publications examined the *RASSF1A* gene promoter hypermethylation status in sputum and other 7 studies used serum. The hypermethylation rate in NSCLC ranged from 16.7% to 85.7%, with the median of 44.5%. However, the hypermethylation rate of *RASSF1A* gene promoter ranged from 0% to 3.3%, a median of 0% in healthy control groups. The main characteristic of the12 publications are shown in [Table 1](#t1-medscimonit-25-5518){ref-type="table"}.

Combined diagnostic sensitivity and specificity
-----------------------------------------------

The chi-square test and I^2^ test demonstrated significant heterogeneity in sensitivity (I^2^=92.6%), ([Figure 2A](#f2-medscimonit-25-5518){ref-type="fig"}). The pooled sensitivity was 0.45 (95%CI: 0.41--0.48) in the random-effects model and the combined diagnostic specificity was 0.99 (95%CI: 0.98--1.00) in the fixed-effects mode ([Figure 2B](#f2-medscimonit-25-5518){ref-type="fig"}).

Combined diagnostic +LR and −LR
-------------------------------

Because of significant heterogeneity, the +LR and −LR were pooled in the random-effects model. The combined +LR and −LR were 20.27 (9.64--42.61) and 0.53 (0.42--0.66), respectively ([Figure 3](#f3-medscimonit-25-5518){ref-type="fig"}).

Combined diagnostic odds ratio
------------------------------

The combined DOR was 46.63 (95%CI: 17.30--125.65) in the fixed-effects model ([Figure 4](#f4-medscimonit-25-5518){ref-type="fig"}).

Combined ROC curve and AUC
--------------------------

The AUC was 0.9989 calculated through Moses's model for *RASSF1A* gene promoter hypermethylation as a biomarker in diagnosis of NSCLC ([Figure 5](#f5-medscimonit-25-5518){ref-type="fig"}).

Publication bias evaluation
---------------------------

Publication bias was evaluated by Egger's line regression, test and no significant publication bias was found (p\>0.05).

Discussion
==========

In China, lung cancer is the leading cause of malignant carcinoma-related mortality for males and the second leading cause of cancer deaths for females \[[@b17-medscimonit-25-5518],[@b18-medscimonit-25-5518]\]. It was reported that in 2018, more than 150 000 lung cancer-related deaths occurred in China \[[@b19-medscimonit-25-5518]\]. Lung cancer has become a serious threaten to health worldwide. Non-small cell lung cancer (NSCLC), accounting for 80% of all lung cancer, is the most common malignant tumor according to clinical diagnosis. Generally, the prognosis of NSCLC is poor, with a total 5-year survival rate of 15.8%. Disease recurrence and remote metastasis are the main causes of treatment failure and death for NSCLC \[[@b20-medscimonit-25-5518]\]. Therefore, early diagnosis or screening of high-risk subjects are key for improving the general prognosis of NSCLC. At present, the most commonly used lung cancer screening or early diagnosis methods are chest radiograph examination, sputum cytology, and chest CT. However, the results of previously studies were not satisfactory because of low sensitivity or low specificity.

Hypermethylation of its CpG-island promoter region of tumor-suppressor genes has been widely discussed as a biomarker for NSCLC diagnosis or screening \[[@b21-medscimonit-25-5518]--[@b23-medscimonit-25-5518]\]. Konecny \[[@b24-medscimonit-25-5518]\] evaluated the value of SHOX2 methylation in serum samples for diagnosis of lung cancer. They found that methylation of the SHOX2 gene is a reliable marker of lung malignancies. Gu et al. performed a meta-analysis evaluating the correlation between P16 gene promoter methylation and lung cancer risk, reporting that the P16 gene promoter hypermethylation rate was significantly different between cancer and autologous normal control tissues, indicating P16 gene promoter hypermethylation is potential biomarker for non-small cell lung cancer diagnosis.

The *RASSF1A* gene is located on chromosome 3 in humans, encoding a protein similar to RAS. *RASSF1A*, also known as ras association domain-containing protein 1 gene, is associated with the pathogenesis of a variety of cancers when there is loss or altered expression of this gene. Promoter region hypermethylation is a known cause of *RASSF1A* gene loss of expression. It has been demonstrated that loss or altered expression of *RASSF1A* is associated with pathogenesis of cervical cancer and lung cancer. It was reported \[[@b25-medscimonit-25-5518]\] that *RASSF1A* was silenced in cancer cells when the promoter region was hypermethylated. The methylation promoter region of *RASSF1A* gene was also widely evaluated in body fluid of NSCLC patients. Huang \[[@b26-medscimonit-25-5518]\] and Wang \[[@b27-medscimonit-25-5518]\] performed 2 meta-analyses relevant to *RASSF1A* hypermethylation and lung cancer, respectively. Huang evaluated the hypermethylation status of cancer tissue versus normal lung tissue, showing a correlation between *RASSF1A* hypermethylation and lung cancer risk. Wang work evaluated the prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma, showing that hypermethylation of RASSF1A is an independent prognostic factor for poor prognosis of NSCLC. However, there has been no previous meta-analysis of its diagnostic performance as a biomarker for NSCLC diagnosis. Therefore, we searched the relevant databases and pooled the relevant studies in order to evaluate the clinical efficacy of *RASSF1A* gene promoter hypermethylation as a biomarker for NSCLC diagnosis. We found that the low diagnostic sensitivity of *RASSF1A* gene promoter hypermethylation indicated it is not suitable for use in NSCLC screening. However, the high specificity made it effective for NSCLC confirmation diagnosis, which can be used instead of pathological diagnosis to some extent.

Conclusions
===========

The low diagnostic sensitivity of *RASSF1A* gene promoter hypermethylation indicates it was not suitable for NSCLC screening. Our study has certain limitations. Firstly, significant heterogeneity was found in the effect size of sensitivity, +LR, −LR, and DOR. Secondly, the general quality of the include studies was poor, especially for Chinese publications. Therefore, large-scale prospective diagnostic trials are needed to further investigate the clinical performance of *RASSF1A* promoter hypermethylation biomarker for NSCLC diagnosis.
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###### 

General characteristics of the 12 included publications.

  First author                            Year   Case   Control   Methods   Specimen         
  --------------------------------------- ------ ------ --------- --------- ---------- ----- --------
  Kang C \[[@b6-medscimonit-25-5518]\]    2011   8      29        0         24         MSP   Sputum
  Ye G \[[@b7-medscimonit-25-5518]\]      2005   5      25        0         27         MSP   Sputum
  Zhou F \[[@b8-medscimonit-25-5518]\]    2014   56     74        1         129        MSP   Serum
  Sun N \[[@b9-medscimonit-25-5518]\]     2012   20     100       4         116        MSP   Sputum
  Shan C \[[@b10-medscimonit-25-5518]\]   2008   16     19        0         15         MSP   Sputum
  Zhai X \[[@b11-medscimonit-25-5518]\]   2014   22     20        0         40         MSP   Serum
  Zhao P \[[@b12-medscimonit-25-5518]\]   2014   28     34        0         46         MSP   Serum
  Wen L \[[@b2-medscimonit-25-5518]\]     2012   45     11        0         52         MSP   Serum
  Peng Z \[[@b13-medscimonit-25-5518]\]   2010   52     30        0         25         MSP   Sputum
  Liu G \[[@b14-medscimonit-25-5518]\]    2007   42     54        0         32         MSP   Serum
  Li W \[[@b15-medscimonit-25-5518]\]     2012   48     8         0         52         MSP   Serum
  Wang Y \[[@b16-medscimonit-25-5518]\]   2007   27     53        0         35         MSP   Serum
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